Source:http://linkedlifedata.com/resource/pubmed/id/11428976
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2001-6-28
|
| pubmed:abstractText |
Cytomegalovirus (CMV) is still a major pathogen in liver transplantation (LTX). The clinical efficacy of prophylactic high-dose acyclovir therapy (800 mg qid) was assessed for the prevention of CMV infection and disease in liver recipients. Fifty-five patients were enrolled in a prospective, randomised, double-blind and placebo-controlled trial; 28 on acyclovir vs. 27 on placebo. The therapy was given for 12 weeks. The patients were followed for 24 weeks. CMV infection was diagnosed in 60% (16 on acyclovir, 17 on placebo) and CMV disease developed in 38% (7 on acyclovir, 14 on placebo) of the patients. The total mortality was 27% (6 on acyclovir, 10 on placebo). Acyclovir delayed 32% of the CMV infections and prevented 59% of the CMV disease cases which occurred in the placebo cohort. The time to CMV disease was significantly prolonged in patients on acyclovir as compared to patients on placebo (P=0.013). Adverse events included neurotoxicity which occurred in 5 cases in the acyclovir, but none in the placebo arm, and nephrotoxicity which was detected in 6 patients in the acyclovir and 5 in the placebo arm, respectively. We conclude that acyclovir prophylaxis significantly reduced the incidence of CMV disease, and delayed the onset of CMV infection in liver transplant patients.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jun
|
| pubmed:issn |
1398-2273
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
1
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
89-97
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11428976-Acyclovir,
pubmed-meshheading:11428976-Administration, Oral,
pubmed-meshheading:11428976-Adult,
pubmed-meshheading:11428976-Aged,
pubmed-meshheading:11428976-Antiviral Agents,
pubmed-meshheading:11428976-Creatinine,
pubmed-meshheading:11428976-Cytomegalovirus Infections,
pubmed-meshheading:11428976-Double-Blind Method,
pubmed-meshheading:11428976-Female,
pubmed-meshheading:11428976-Graft Survival,
pubmed-meshheading:11428976-Herpes Simplex,
pubmed-meshheading:11428976-Humans,
pubmed-meshheading:11428976-Injections, Intravenous,
pubmed-meshheading:11428976-Liver Transplantation,
pubmed-meshheading:11428976-Male,
pubmed-meshheading:11428976-Middle Aged,
pubmed-meshheading:11428976-Monitoring, Physiologic,
pubmed-meshheading:11428976-Placebos,
pubmed-meshheading:11428976-Postoperative Complications,
pubmed-meshheading:11428976-Proportional Hazards Models,
pubmed-meshheading:11428976-Time Factors
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients.
|
| pubmed:affiliation |
Division of Transplantation Surgery, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden. lisbeth.barkholt@impi.ki.se
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|